Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mutated and Wild Type Acute Myeloid Leukemia: A Medical Chart Study

European Journal of Haematology. December 22, 2018

OBJECTIVES:

To assess real-world treatment patterns and healthcare resource utilization (HRU) among patients with FLT3-mutated(FLT3mut ) and FLT3-wild-type (FLT3wt ) acute myeloid leukemia (AML).

METHODS:

Data were abstracted from medical charts of patients with AML from 10 countries. Patients were grouped based on their FLT3 mutation status, age (18-64 or ≥65), and whether they were newly diagnosed (ND) or relapsed/refractory (R/R).

RESULTS:

Charts of 1027 AML patients were included (183 FLT3mut 18-64 ND; 136 FLT3mut ≥65 ND; 181 FLT3mut R/R; 186 FLT3wt 18-64 ND; 159 FLT3wt ≥65 ND; 182 FLT3wt R/R). Substantial heterogeneity was observed in treatment patterns for AML. Among ND patients 18-64, the most common initial treatment was standard-to-intermediate dose cytarabine-based therapies (43.2% for FLT3mut and 55.9% for FLT3wt); among ND patients ≥65, the most common initial treatment was hypomethylating agent-based therapies (36.0% and 47.2%). Among R/R patients, the most common initial treatment after R/R was best supportive care only (39.8% and 24.7%). HRU was substantial across cohorts during both event-free and post-event periods.

CONCLUSIONS:

Treatment patterns of AML were heterogeneous and FLT3mut AML was treated more aggressively than FLT3wt disease. HRU was substantial for all cohorts, particularly after relapse or treatment failure.

View abstract

Authors

Griffin JD, Yang H, Song Y, Kinrich D, Shah MV, Bui CN